acimmune.com - ACIU EV/Sales Multiple

Official company branding of AC Immune SA (ACIU)

AC Immune is scaling its precision neurodegeneration therapy portfolio through global R&D partnerships. Long-term patents and upfront payments from pharma behemoths provide stable funding, while manufacturing outsourcing allows the company to focus on development. The enterprise value-to-revenue ratio illustrates the search for market equilibrium, while 5323.19 shows the current volume of the total valuation metric.

AC Immune (ACIU) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

ACIU (AC Immune): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:ACIU, AC Immune SA
Mass-produced product of AC Immune Inc

This ratio compares the enterprise value, including net debt, to the company's sales volume. By analyzing the EV/Revenue value on the GURU.Markets platform, an investor assesses the capitalization efficiency of operating income. The current level of 5323.19 reflects market expectations regarding the company's resilience to external shocks. This metric confirms the fundamental reliability of the business. The high authority of AC Immune (ACIU) in Alzheimer's therapy and its partnerships with pharma behemoths justify the current valuation.

Direct competitors

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE